• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.

    7/2/25 4:05:21 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Neuraxis, Inc

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    64134X201

    (CUSIP Number)


    07/01/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    64134X201


    1Names of Reporting Persons

    Brian P. Hannasch
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,144,374.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,144,374.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,144,374.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares disclosed above include 12,852 shares of common stock of Neuraxis, Inc. issuable upon the exercise of currently exercisable warrants held by Mr. Hannasch.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Neuraxis, Inc
    (b)Address of issuer's principal executive offices:

    11611 N. Meridian Street, Suite 330, Carmel, IN, 46032
    Item 2. 
    (a)Name of person filing:

    Brian P. Hannasch
    (b)Address or principal business office or, if none, residence:

    8815 W. State Road 46, Columbus, Indiana 47201
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    64134X201
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,144,374
    (b)Percent of class:

    12.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,144,374

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,144,374

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Brian P. Hannasch
     
    Signature:/s/ Brian P. Hannasch
    Name/Title:Brian P. Hannasch
    Date:07/02/2025
    Get the next $NRXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

    Achieves significant expansion of NeurAxis' total addressable marketClearance now includes patients aged "8 years and older"Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated

    10/24/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

    CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 11:00 a.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at

    9/18/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Carrico Brian Allen

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:56 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:53 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferge Kristin A was granted 13,157 shares, increasing direct ownership by 1,112% to 14,340 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:54 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hannasch Brian bought $800,001 worth of shares (355,556 units at $2.25), increasing direct ownership by 46% to 1,131,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    7/3/25 11:24:27 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    4/23/25 4:38:50 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    SEC Filings

    View All

    Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/24/25 8:22:36 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:27:48 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Neuraxis Inc.

    424B5 - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:26:10 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    View All

    NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

    CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

    1/31/24 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Financials

    Live finance-specific insights

    View All

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

    CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi

    8/5/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

    CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

    5/12/25 8:15:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuraxis Inc.

    SC 13D - Neuraxis, INC (0001933567) (Subject)

    12/2/24 11:53:07 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Neuraxis Inc.

    SC 13G - Neuraxis, INC (0001933567) (Subject)

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    SC 13G/A - Neuraxis, INC (0001933567) (Subject)

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care